Ceftriaxone in the treatment of Lyme neuroborreliosis
Language English Country Germany Media print
Document type Clinical Trial, Journal Article
PubMed
8852479
DOI
10.1007/bf01780667
Knihovny.cz E-resources
- MeSH
- Borrelia burgdorferi Group immunology isolation & purification ultrastructure MeSH
- Ceftriaxone therapeutic use MeSH
- Child MeSH
- Adult MeSH
- Ticks MeSH
- Humans MeSH
- Lyme Disease drug therapy immunology microbiology pathology MeSH
- Nervous System Diseases drug therapy immunology microbiology pathology MeSH
- Antibodies, Bacterial blood MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Names of Substances
- Ceftriaxone MeSH
- Antibodies, Bacterial MeSH
In an open non-comparative clinical trial with the aim of evaluating the clinical efficacy and safety of a 14 day course of 2 g ceftriaxone once daily, 46 patients with neuroborreliosis were entered at the Infectious Diseases Teaching Hospital in Prague 8. In 39 patients the diagnosis was early Lyme neuroborreliosis. Seven patients suffered from late stage disease. Clinical results were 30% of patients cured at the end of treatment and 85% after 9 months in early stage disease. In late stage disease two patients out of seven were cured and four had improved after 12 months. One patient died because of cardiac infarction. In no patient had treatment to be discontinued because of adverse reactions to antibiotics.
